Literature DB >> 31077832

Risk Factors, Endoscopic Features, and Clinical Outcomes of Cytomegalovirus Esophagitis Based on a 10-year Analysis at a Single Center.

Patrick Hoversten1, Amrit K Kamboj1, Tsung-Teh Wu2, David A Katzka3.   

Abstract

Cytomegalovirus (CMV) can infect multiple areas of the gastrointestinal tract, most commonly the esophagus and colon.1 CMV esophagitis is the third leading cause of infectious esophagitis, after Candida and herpes simplex virus.2 It occurs predominantly in immunocompromised hosts such as patients with human immunodeficiency virus (HIV) and is considered an acquired immunodeficiency syndrome (AIDS) defining illness.1 However, more recent case reports suggest that this disease may also affect the non-HIV immunosuppressed patient population.3 The aim of this study was to reevaluate predictors for development of CMV esophagitis in the post highly active antiretroviral therapy era and describe clinical and endoscopic features of CMV esophagitis as well as patient outcomes from a large tertiary care center.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31077832     DOI: 10.1016/j.cgh.2019.04.066

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  2 in total

1.  Infectious Esophagitis in Romanian Children: From Etiology and Risk Factors to Clinical Characteristics and Endoscopic Features.

Authors:  Mădălina Adriana Bordea; Alexandru Pîrvan; Dan Gheban; Ciprian Silaghi; Iulia Lupan; Gabriel Samașca; Lia Pepelea; Lia Monica Junie; Carmen Costache
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

2.  Risk Factors, Clinical and Endoscopic Features, and Clinical Outcomes in Patients with Cytomegalovirus Esophagitis.

Authors:  Pai-Jui Yeh; Ren-Chin Wu; Chien-Ming Chen; Cheng-Tang Chiu; Ming-Wei Lai; Chien-Chang Chen; Chia-Jung Kuo; Jun-Te Hsu; Ming-Yao Su; Puo-Hsien Le
Journal:  J Clin Med       Date:  2022-03-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.